Results for: Drug Discovery

The global cell-based assays market is projected to reach US$ 40.4 billion by 2034, driven by increasing demand for drug development and biomedical research. Cell-based assays provide several advantages over traditional methods, offering a more accurate and physiologically relevant approach to analyzing drug properties. The market is segmented by product type, application, end user, and region, with North America leading the market due to significant drug discovery research and rising prevalence of chronic illnesses.

The global AI in pharma and biotech market is projected to reach US$ 13.1 billion by 2034, driven by the rapid adoption of AI-powered tools for drug discovery, clinical trials, and personalized medicine. AI is transforming drug development, improving clinical trial efficiency, and enabling personalized treatment plans.

The world is grappling with the rising threat of antibiotic-resistant bacteria, a silent pandemic that has already claimed millions of lives. Researchers are exploring innovative approaches to combat this crisis, aiming to restore the effectiveness of existing antibiotics and develop new treatments. This article explores the mechanisms behind antibiotic resistance, the challenges it poses, and the promising strategies being developed to fight back.

Artificial intelligence (AI) holds immense promise for revolutionizing healthcare, enabling improved diagnostics, personalized patient support, accelerated drug discovery, and increased efficiency. However, despite years of research, its integration into mainstream healthcare has been slow. This article explores the reasons behind this slow adoption, including data fragmentation, privacy concerns, regulatory challenges, and misaligned incentives. By addressing these obstacles, governments, regulators, and healthcare providers can unlock the full potential of AI to transform medical practices, improve outcomes, and save lives.

Despite strong quarterly results and a promising pipeline, ClearPoint Neuro’s stock has faced headwinds due to macro conditions and interest rate fears. However, the company’s fundamentals remain solid, with revenue growth expected in 2024 and cash burn moderating. New product commercialization and operating leverage will drive profitability, but drug discovery revenue could be affected by higher interest rates.

Evotec SE, a drug discovery company, has experienced a sharp decline in its stock price following the release of its financial results. While the company’s growth prospects remain promising, concerns over its competitive landscape, execution challenges, and valuation have contributed to the sell-off. Nevertheless, the author remains cautiously optimistic about the company’s long-term potential, classifying it as a speculative buy due to its attractive pipeline and growth potential.

Researchers have developed an AI model called SyntheMol that can design entirely new molecules, including potential antibiotics. This model has generated six novel drugs aimed at killing resistant strains of Acinetobacter baumannii, one of the leading pathogens responsible for antibacterial resistance-related deaths. These new compounds have shown promise in fighting other infectious bacteria as well, including E. coli, MRSA, and those that can cause meningitis and pneumonia.

The DigiPharmaX Awards 2024 honors the groundbreaking achievements of pharmaceutical companies and individuals shaping the future of healthcare. These prestigious awards celebrate the advancements in research, innovation, and patient care that are transforming the industry. Join us as we recognize the pioneers at the forefront of pharmaceutical excellence.